Medical misdiagnoses account for almost 800,000 deaths and other serious harms every year. Meanwhile healthcare AI is roundly celebrated for its diagnostic prowess. Can’t it help cut out a couple hundred thousand of those horrible mistakes?
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities.
The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.
Patients first sued the St. Louis Park, Minnesota-based imaging group in two separate lawsuits, both filed in 2023, over its use of tracking pixels to allegedly filter info to Facebook and other third parties.
Founded in 2023, Hunterbrook is an investigative news and investment outlet, which creates reports criticizing publicly traded companies and then benefits from the corresponding drop in share prices
In total, 22 facilities will benefit from the money, provided by the Statewide Health Care Facility Transformation Program. Projects include cybersecurity upgrades and telehealth implementation, in addition to EHR upgrades.
By signing an executive order, President Donald Trump has shifted marijuana from a Schedule I to a Schedule III controlled substance, opening the door for medical and research uses nationwide.
The Soft-Tissue Tumor Reporting and Data System (ST-RADS) is an MRI framework that was designed to assess the risk of soft tissue tumors and help providers in managing the finding.
Medical misdiagnoses account for almost 800,000 deaths and other serious harms every year. Meanwhile healthcare AI is roundly celebrated for its diagnostic prowess. Can’t it help cut out a couple hundred thousand of those horrible mistakes?
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities.
